Share:
Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show.
Read the full story at The New York Times.
Source : The New York Times
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.